Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $16.00 | Outperform | Leerink Partners |
| 10/14/2024 | $16.00 | Buy | Guggenheim |
| 9/30/2024 | Outperform | William Blair |
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the third quarter of 2024 and provided a corporate update. "The third quarter showcased strong execution across our compa
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast. Format: Fireside Chat Presenter: Chris Giordano, President & Chief Executive OfficerDate and ti
SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. The company's market cap stands at $1.5 million. The company's, Q1 earnings came out 2 days ago. Sharps Technology (NASDAQ:STSS) stock rose 33.56% to $0.31. The market value of their outstanding shares is at $6.1 million. Autonomix Medical (NASDAQ:AMIX) shares increased by 21.43% to $0.78. The market value of their outstanding shares is at $14.6 million. Akso Health Group (NASDAQ:AHG) stock rose 11.68% to $1.29. The company's market cap stands at $189.2 million. Conduit Pharmaceuticals (NASDAQ:CDT) stock rose 10.74% to $0.71. The company's market cap stands at $52.3 mill
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2.40) by 30 percent. This is a 74 percent increase over losses of $(12.00) per share from the same period last year.
Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00
Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00
William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company's PH-HFpEF Scientific Advisory Board (SAB). "We are thrilled to welcome Dr. Butler to our Scientific Advisory Board," said Stuart Rich, M.D., Chief Medical Officer of Tenax Therapeutics. "Javed is regarded as one of the most eminent clinical trialists in cardiovascular medicine, and he joins three highly distinguished cardiovascular lead
MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022. Ms. Hunter is an independent director and will chair the Board's audit and compliance committee. "We are very pleased to welcome Robyn to our Board of Directors," said Christopher T. Giordano, President and Chief Executive Officer of Tenax Therapeutics. "Robyn brings a wealth of financial and operational